The expression of miR‐130a has been examined in ovarian cancer cells, and it is involved in the cell activities and drug resistance.16 MiR‐130a may be a potential treatment target in ovarian cancers through inhibiting PTEN to activate PI3K/AKT signalling pathway.34 According to a previous integrated gene network analysis, miR‐130a expression is associated with multidrug resistance in epithelial ovarian cancer by binding to NRP1.35 MiR‐130a enhanced proliferation and inhibits apoptosis of ovarian granulosa cells in the rat models of PCOS of this study. Here, NRP1 is linked to ovarian carcinoma.